Abstract
The T11 sheep erythrocyte binding glycoprotein1–4 [relative molecular mass (Mr) 50,000 (50K)] is expressed throughout human T-lymphocyte ontogeny and appears to play an important physiological role in T-cell activation5. Thus, the treatment of T cells with certain monoclonal anti-T11 antibodies results in antigen-independent polyclonal T-cell activation as assessed by proliferation and lymphokine secretion. In addition, the majority of thymocytes that have not yet acquired the T3–Ti antigen/major histocompatibility complex (MHC) receptor can be activated to express interleukin-2 (IL-2) receptors through this T11 structure6,7. We show here that the triggering of cytolytic T (Tc) cells via T11 causes an antigen-independent activation of the cytolytic mechanism as evidenced by the induction of nonspecific cytolytic activity. Furthermore, T11+T3−Ti− natural killer (NK) cell clones can also be induced to lyse NK-cell-resistant targets by treatment with anti-T11 monoclonal antibodies directed at defined T11 epitopes. These results indicate that T11 triggering can activate cytotoxic lymphocytes to express their functional programmes in the absence of specific antigen recognition via the T3–Ti complex and provide further evidence for the notion that certain NK cells and T lymphocytes are related.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Howard, F. D. et al. J. Immun. 126, 2117–2122 (1981).
Kamoun, M. et al. J. exp. Med. 153, 207–212 (1981).
Bernard, A. et al. 155, 1317–1333 (1982).
Verbi, W. et al. Eur. J. Immun. 12, 81–86 (1982).
Meuer, S. C. et al. Cell 36, 897–906 (1984).
Acuto, O. et al. Cell 34, 717–726 (1983).
Fox, D. A. et al. J. Immun. 134, 330–335 (1985).
Martin, P. J. et al. J. Immun. 131, 180–185 (1983).
Krensky, A. M. et al. J. Immun. 131, 611–616 (1983).
Meuer, S. C. et al. Science 218, 471–473 (1982).
Chilson, O., Boysteon, A. W. & Crumpton, M. J. EMBO J. 3, 3239 (1984).
O'Flynn, K., Krensky, A. M., Beverley, P. C. L., Burakoff, S. J. & Linch, D. C. Nature 313, 686–687 (1985).
Plaut, M., Bubbers, J. E. & Henney, C. S. J. Immun. 116, 150–155 (1976).
Goldstein, P. & Smith, E. T. Eur. J. Immun. 6, 31–37 (1975).
Martez, E. Contemp. Topics Immunobiol. 7, 301–316 (1977).
Bhakdi, S. & Tranum-Jensen, J. Proc. natn. Acad. Sci. U.S.A. 75, 5655–5659 (1978).
Bhakdi, S., Fussle, R. & Tranum-Jensen, J. Proc. natn. Acad. Sci. U.S.A. 78, 5475–5479 (1981).
Podack, E. R. & Konigsberg, P. J. J. exp. Med. 160, 693–710 (1984).
Henkart, P. A., Millard, P. J., Reynolds, C. W. & Henkart, M. P. J. exp. Med. 160, 75–93 (1984).
Devlin, J. J. et al. Lymphokines 9, 313–336 (1984).
Schmid, D. S., Powell, M. B., Mahoney, K. A. & Ruddle, N. H. Cell. Immun. (in the press).
Landegren, U. et al. J. exp. Med. 155, 1579–1584 (1982).
Hercend, T., Reinherz, E. L., Meuer, S. C., Schlossman, S. F. & Ritz, J. Nature 301, 158–160 (1983).
Ritz, J. et al. Science 228, 1540–1543 (1985).
Royer, H. D., Ramarli, D., Acuto, O., Campen, T. J. & Reinherz, E. L. Proc. natn. Acad. Sci. U.S.A. (in the press).
Yanagi, Y. et al. Nature 314, 631–633 (1985).
Spits, H., Yssel, H., Leeuwenberg, J. & DeVries, J. E. Eur. J. Immun. 15, 88–91 (1985).
Reinherz, E. L. et al. Cell 30, 735–743 (1982).
Meuer, S. C. et al. Nature 303, 808–810 (1983).
Weiss, M. J., Daley, J. F., Hodgdon, J. C. & Reinherz, E. L. Proc. natn. Acad. Sci. U.S.A. 81, 6836–6840 (1984).
Weiss, A., Imboden, J., Shoback, D. & Stobo, J. Proc. natn. Acad. Sci. U.S.A. 81, 4169–4173 (1984).
O'Flynn, K., Linch, D. C. & Tatham, P. E. R. Biochem. J. 219, 661–666 (1984).
O'Flynn, K. Eur. J. Immun. 15, 7–11 (1985).
Oettgen, H. C., Terhorst, C., Cantley, L. C. & Rosoff, P. M. Cell 40, 583–590 (1985).
Meuer, S. C., Schlossman, S. F. & Reinherz, E. L. Proc. natn. Acad. Sci. U.S.A. 79, 4395–4399 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siliciano, R., Pratt, J., Schmidt, R. et al. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature 317, 428–430 (1985). https://doi.org/10.1038/317428a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/317428a0
This article is cited by
-
The cancer–natural killer cell immunity cycle
Nature Reviews Cancer (2020)
-
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Journal for ImmunoTherapy of Cancer (2017)
-
Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status
BMC Immunology (2006)
-
Natural killer cells, viruses and cancer
Nature Reviews Immunology (2001)
-
Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein
Cancer Immunology Immunotherapy (1995)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.